ten23 expands manufacturing; adds QC services

CDMO ten23 has expanded manufacturing capacity of sterile drug products at its Visp, Switzerland facility and will add quality control services in 2024.

The Swiss contract development and manufacturing organization (CDMO) ten23 Health confirmed that, after a successful GMP inspection by Swissmedic, its new storage areas in the VIVA facility in Visp, Switzerland are operational. The output of its sterile manufacturing area will gradually increase by 50%.

“We are thrilled to offer our customers additional sterile manufacturing capacity for sophisticated and highly precise drug product-presentations such as syringes and cartridges, increased capacity until the two new production lines becoming fully operational,” says CEO Hanns-Christian Mahler.

DepositPhotos/unkreatives

The expansion, announced last year, will be complemented by two additional filing lines currently being built at the VIVA 2 facility.  Line 2 will be for sterile commercial supplies of ready to use syringes, cartridges and vials, while line 3 will be dedicated to liquid or freeze-dried clinical and commercial vial supplies.

This project is on track with a first customer project and tech transfer is signed for manufacturing in 2024 and 2025.

“With recent demand increases for clinical as well as commercial drug launches, our customers are keen to take advantage of increased capacity from the existing VIVA 1 facility, before the new plant VIVA 2 will be utilized for larger scales,” Mahler adds.

In its bid to become an integrated solution provider, the CDMO has also confirmed quality control (QC) services will be introduced in both its Basel and Visp facilities.

In Basel, ten23 will offer physico-chemical testing, while microbiological quality control services will be the focus in Visp.

“We are excited to announce the expansion and the launch of our quality control services,” says Mahler. “By adding these services, we aim to streamline the development, testing and manufacturing processes for our clients, enabling them to focus on their core competencies while we can handle their needs for pharmaceutical development, sterile manufacturing and testing.”

The new quality control services will be available from Q2 2024.